Skip to main content
SpringerLink
Log in

Afatinib

Lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Uji E, et al. P28-14 Long-term response to alectinib in a patient with ALK-fusion gene emerged in afatinib-resistant EGFR-mutated lung cancer. Annals of Oncology 33 (Suppl. 6): S523, Jul 2022. Available from: URL: http://doi.org/10.1016/j.annonc.2022.05.275 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib. Reactions Weekly 1919, 27 (2022). https://doi.org/10.1007/s40278-022-20969-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-20969-y

Search

Navigation